Evidence map›Paper›PMID 37861205›Full record

ArticleInternational journal of cancer2024

Plasma cell-free DNA methylation analysis for ovarian cancer detection: Analysis of samples from a case-control study and an ovarian cancer screening trial.

Chiara Herzog, Allison Jones, Iona Evans, Daniel Reisel, Adeola Olaitan, Konstantinos Doufekas, Nicola MacDonald, Angelique Flöter Rådestad, Kristina Gemzell-Danielsson, Michal Zikan and 11 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 6 institutions in 5 countries.

Chiara HerzogEuropean Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria.ORCID 0000-0002-1572-498X
Allison JonesDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Iona EvansDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Daniel ReiselDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Adeola OlaitanDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Konstantinos DoufekasDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Nicola MacDonaldDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Angelique Flöter RådestadDepartment of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Kristina Gemzell-DanielssonDepartment of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Michal ZikanDepartment of Gynecology and Obstetrics, Charles University in Prague, First Faculty of Medicine and Hospital, Na Bulovce, Czech Republic.
David CibulaDepartment of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic.
Lukáš DostálekDepartment of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University, Prague and, General University Hospital, Prague, Czech Republic.
Tobias PaprotkaGENEWIZ Germany GmbH, Bahnhofstraße, Germany.
Andreas LeimbachEurofins Genomics Europe Sequencing GmbH, Konstanz, Germany.
Markus SchmittEurofins Genomics Europe Sequencing GmbH, Konstanz, Germany.
Andy RyanMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Aleksandra Gentry-MaharajDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Sophia ApostolidouMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.
Adam N RosenthalDepartment of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
Usha MenonMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.ORCID 0000-0003-3708-1732
Martin WidschwendterEuropean Translational Oncology Prevention and Screening (EUTOPS) Institute, Hall in Tirol, Austria.ORCID 0000-0002-7778-8380
London Women's Clinic · GBMRC Clinical Trials Unit at UCL · GBCharles University · CZKarolinska University Hospital · SEEurofins (Germany) · DEUniversität Innsbruck · AT

Funding

European Research Council 742432Medical Research Council MC_UU_00004/01
6 · The paper itself

Abstract

Analysis of cell-free DNA methylation (cfDNAme), alone or combined with CA125, could help to detect ovarian cancers earlier and may reduce mortality. We assessed cfDNAme in regions of ZNF154, C2CD4D and WNT6 via targeted bisulfite sequencing in diagnostic and early detection (preceding diagnosis) settings. Diagnostic samples were obtained via prospective blood collection in cell-free DNA tubes in a convenience series of patients with a pelvic mass. Early detection samples were matched case-control samples derived from the UK Familial Ovarian Cancer Screening Study (UKFOCSS). In the diagnostic set (n

Indexed as

DNA MethylationOvarian NeoplasmsBiomarkers, TumorCA-125 AntigenCase-Control StudiesEarly Detection of CancerFemaleHumansKruppel-Like Transcription FactorsProspective StudiesBiomarkers, TumorCA-125 AntigenKruppel-Like Transcription FactorsZNF154 protein, humancell-free DNAdiagnosismethylationovarian cancer

Identifiers

PMID37861205
PMCPMC7617350
OpenAlexW4387798207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.